S&P affirms Watson

Standard & Poor's said that it affirmed the BBB corporate credit, senior unsecured and bank loan ratings on Watson Pharmaceuticals Inc.

The stable outlook reflects the expectation that Watson will continue to pursue acquisitions in a manner that preserves its financial risk profile, the agency said.

The ratings on Watson Pharmaceuticals reflect the expectation of high-single- to low-double-digit EBITDA growth over the next few years, while leverage measures will remain consistent with an intermediate financial risk profile or better, the agency added.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.